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Abstract 
The cellular retinoic acid binding protein type I (CRABP-I) shows a highly specific expression pattern during mouse embryonic 
development. The tissues that express CRABP-I, i.e. the central nervous system (CNS), neural crest, branchial arches, limb bud and 
frontonasal mass, coincide with those that are most sensitive to unphysiological retinoic acid (RA) concentrations. We have investigated the 
transcriptional elements that are responsible for the spatiotemporal regulation of CRABP-I expression in the mouse embryo. We show here 
that a 16 kb fragment harbours all the elements needed for the correct spatiotemporal expression pattern. Upon further dissection of this 
fragment we have found that expression in the CNS is driven by elements in the upstream region of the gene, while expression in 
mesenchymal and neural crest tissue is regulated via element(s) located downstream of exon II of the gene. Two distinct fragments in 
the upstream region are required for expression in the CNS, as neither of these fragments alone is able to drive correct expression of a 
reporter gene in transgenic mice. DNAseI footprinting analysis of the two upstream fragments revealed the presence of a number of 
protected elements. One of these regulatory elements has the hallmarks of an RA response element, suggesting that CRABP-I expression in 
neural tissue can be directly modulated by RA via the RARs/RXRs. 0 1997 Elsevier Science Ireland Ltd. 
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1. Introduction 
Retinoic acid (RA), a naturally occurring metabolite of 
vitamin A, plays a vital role in normal physiology of verte- 
brates. Maintenance of physiological levels of RA is impor- 
tant for correct embryonic development since both excess 
and deficiency of RA result in a spectrum of congenital 
malformations. Under normal conditions RA is believed 
to be involved in the anterior-posterior patterning of the 
embryo, including the central nervous system (CNS) 
(Means and Gudas, 1995). 
The profound effects of RA on biological systems are 
mediated through two classes of proteins, i.e. the retinoic 
acid receptors (RARs and RXRs) and the cellular retinoic 
acid binding proteins (CRABPs). The RARs/RXRs are 
ligand inducible nuclear receptors belonging to the ster- 
oid/thyroid hormone receptor superfamily (Mangelsdorf et 
al., 1995; Chambon, 1996). They regulate gene expression 
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through binding as heterodimers to specific DNA 
sequences, RA response elements (RAREs), contained in 
the regulatory regions of responsive genes. Within each 
receptor family (RAR or RXR), three different genes have 
been identified, each giving rise to multiple isoforms (Leid 
et al., 1992). The CRABPs are small intracellular proteins 
that bind RA with high affinity. Two highly homologous but 
different CRABP genes (CRABP-I and CRABP-II) have 
been cloned in a number of species. They appear to be 
highly conserved through vertebrate evolution. Each 
CRABP specifically binds RA, with a higher affinity than 
the RARs. The RA binding affinity of CRABP-I is four-fold 
higher than that of CRABP-II (Norris et al., 1994; Napoli et 
al., 1995). They are likely to have a role in regulating the 
availability of RA to the nuclear receptors, but their exact 
function remains to be demonstrated. 
CRABP-I shows a spatiotemporally specific expression 
pattern during embryonic development, with expression 
found in the central nervous system (CNS), the neural 
crest, the dorsal root ganglia, the limb bud a$d the fronto- 
nasal mass (Ruberte et al., 1991, 1992; Lyn and Giguere, 
1994; Horton and Maden, 1995). In the limb bud a graded 
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distribution of CRABP has been found along the proximo/ 
distal axis. Some authors have also observed a gradient 
along the anterior/posterior (A/P) axis of the limb (Maden 
et al., 1988; Perez-Castro et al., 1989), but the presence of 
an A/P gradient was not found by others (Dolle et al., 1989; 
Ruberte et al., 1992). In the CNS the protein is expressed in 
the outer layer of the midbrain roof, in the hindbrain and in 
the mantle layer of the neural tube. Interestingly these sites 
of expression coincide with the structures that are most 
sensitive to RA excess (Vaessen et al., 1990). Both 
CRABP-I and CRABP-YCRABP-II deficient mice have 
been generated (de Bruijn et al., 1994; Gorry et al., 1994; 
Lampron et al., 1995), but as yet no abnormal phenotype has 
been observed in these mice. It has been suggested that the 
function of CRABP-I may only become apparent under 
conditions of RA deficiency, when it could preferentially 
sequester RA in those tissues that are critically dependent on 
the availability of the ligand (Lampron et al., 1995). Over- 
expression of the protein in F9 cells (Boylan and Gudas, 
1991) and ectopic expression of the protein under control of 
a heterologous promoter in transgenic mice (Wei and Chen, 
1991; Perez-Castro et al., 1993) have both been shown to 
interfere with normal cellular differentiation, Overexpres- 
sion of CRABP (xCRABP) in Xenopus was found to cause 
anteroposterior defects in developing embryos (Dekker et 
al., 1994). Thus, while the knock-out of CRABP-I did not 
reveal a function, overexpression of the protein may give 
some indication of its role in embryonic development. 
Knowledge of the regulatory elements would open the pos- 
sibility of overexpressing CRABP-I within its endogenous 
expression domain, or in specific subdomains thereof, and 
provides a means to characterise the transcription factors 
that play a role in early neural and neural crest development. 
We show here that a 16 kb construct, GCTag, is able to 
regenerate the complete expression pattern of endogenous 
CRABP-I. Deletional analysis of this construct revealed that 
the expression pattern of the transgenic CRABP can be split 
into two domains, i.e. a neural and a mesenchymaYneura1 
crest component. Expression in the mesenchymal/neural 
crest domain is driven by element(s) located downstream 
of exon II of the gene. The enhancer region that directs the 
expression of CRABP-I in the neural domain was studied 
further, leading to the identification of four regulatory ele- 
ments. One of these elements is a putative RA response 
element, which would allow for modulation of CRABP-I 
expression by RA. The other three elements are apparently 
able to bind multiple factors, suggesting that a complex 
interplay of transcription factors regulates the expression 
of CRABP-I during murine embryonic development. 
2. Results 
To define the genomic sequences that direct the expres- 
sion of the CRABP-I gene in the mouse embryo we have 
generated a number of genomic reporter constructs from the 
CRABP-I locus and analysed their expression patterns in 
transgenic founder embryos and transgenic lines at various 
developmental stages. The constructs used for micro-injec- 
tion in this study are illustrated in Fig. 1. In order to preserve 
the genomic organisation of the locus as much as possible 
the transgenic constructs consist of fragments from the mur- 
ine CRABP-I locus containing the complete CRABP-I cod- 
ing region. To distinguish between expression of the 
transgene and the endogenous CRABP-I, the transgenic 
CRABP has been marked with an epitope tag derived 
from the human c-myc proto-oncogene (Evan et al., 
1985). Using site-directed mutagenesis an NcoI restriction 
site was created at the translational start site of the CRABP-I 
gene, into which the Myc epitope tag was cloned. Con- 
structs containing this tagged CRABP-I, hereafter referred 
to as CRABP-Tag, were microinjected into mouse oocytes. 
Embryos that were identified as transgenic by Southern 
blotting were embedded, sectioned and stained for 
CRABP-I and for the Myc-tag. 
2.1. A 16 kb fragmeat GCTag can regenerate the CRABP-I 
expression pattern 
The cosmid construct M4Tag contains 40 kb of the 
CRABP-I locus, of which 20 kb is located upstream of the 
CRABP-I start site. Five independent lines were obtained 
that were transgenic for this construct. Two out of the five 
lines did not show expression of the transgene, probably due 
to integration in an area of the mouse genome that is tran- 
scriptionally silent. Injection of the 16 kb fragment GCTag, 
with 3.2 kb upstream sequences and 13 kb downstream 
sequences yielded seven independent transgenic animals. 
Four were bred as lines and three were isolated as founder 
embryos. Of the founder embryos two did not express the 
transgene. The expression patterns of the transgenes M4Tag 
and GCTag were essentially identical. The expression pat- 
terns of CRABP-Tag in the expressing lines were analysed 
in embryos at midgestational stages. Expression of CRABP- 
Tag in these embryos was found in the central nervous 
system, the limb buds, the mesenchyme in the mesonephric 
area and in the frontonasal mass (Fig. 2A-D). In the CNS 
staining for CRABP-Tag is found in the outer layer of the 
midbrain, in the hindbrain and in the mantle layer of the 
neural tube. In a 10.5 d.p.c. embryo staining is found in the 
outer layer of the hindbrain and throughout the thickness of 
rhombomeres 2, 4, 5 and 6, while being absent from rhom- 
bomeres 1 and 3 (Fig. 2C), as has been found for endogen- 
ous CRABP-I (Maden et al., 1992; Leonard et al., 1995). At 
later stages CRABP-Tag staining in the hindbrain is only 
found in the outer layer. Migrating neural crest cells on 
either side of the neural tube and the neural crest derived 
dorsal root ganglia are also positive for CRABP-Tag (Fig. 
3A,B). In the limb buds of 10.5 d.p.c. embryos CRABP-Tag 
staining is found in a graded manner with the highest levels 
found at the distal end (Fig. 2D). We found no consistent 
evidence for a graded distribution along the anteroposterior 
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Fig. 1. (A) Genomic locus of murine CRABP-I. Black boxes indicate the four exons of the gene. (B) Fragments used to generate transgenic mice. All 
fragments contain the complete CRABP-I coding sequences, into which an epitope tag, derived from human c-myc, has been inserted. M4Tag contains 20 kb 
upstream sequences and 20 kb downstream sequences. The 16 kb fragment GCTag contains 3.2 kb upstream sequences and 13 kb downstream sequences. 
XHTag has 1.1 kb upstream sequences and 13 kb downstream sequences. ECTag contains 3.2 kb upstream sequences and is fused in exon II to the CRABP-I 
cDNA. SCTag and XCTag are derived from ECTag and contain 1.7 and 1 .O kb of the upstream region, respectively. The table on the right side indicates the 
expression of the different constructs in transgenic mice. The first column shows the number of transgenic mice, the second column shows the number of 
mice that express the transgene and the third column shows the site of expression. N indicates expression in the neural subdomain of CRABP-I expressing 
cells. M + NC indicates expression in neural crest cells and the mesenchymal subdomain of CRABP-I expressing cells. 
axis. At 13.5 days CRABP-Tag protein is found in the prox- 
imal interdigital region in the cells surrounding the cartila- 
ginous condensations (data not shown). In addition to this 
we find expression in the otic vesicle (Fig. 2B,D). This 
pattern of expression is consistent with the endogenous 
expression pattern of CRABP-I. These results show that 
the 16 kb fragment GCTag contains all the elements 
required for the correct regulation of CRABP-I expression 
during mouse embryogenesis. 
2.2. TIze CRAW-1 expression pattera can be d~v~ded into a 
neural and a mesenchymallneural crest component 
In order to further localise the elements regulating 
CRABP-I expression we made the const~cts ECTag, 
XHTag, SCTag and XCTag (see Fig. 1). ECTag is a hybrid 
genomic/cDNA construct, containing 3 kb of 5’ sequences, 
the first exon containing the Myc-tag, the first intron and the 
cDNA sequences of exons 2, 3 and 4. This fragment was 
injected to determine the presence of regulatory sequences 
in the 5’ region of the gene. Six out of seven ECTag lines 
showed expression of the transgene, but expression was 
found only in the midbrain, the hindbrain and the ventral 
aspect of the mantle layer of the neural tube, i.e. the neural 
tissues that express CRABP-I (Figs. 2H,I and 3E,F). None 
showed expression in any of the other CRABP-I expression 
sites. None of eight SCTag and XCTag lines, which contain 
1.7 and 1.0 kb of upstream sequences, the tagged exon 1, 
intron 1 and exons 2, 3 and 4 from the cDNA were 
expressed. Thus, the minimal promoter egion is insufficient 
to direct expression without the upstream sequences 
between EcoRI and XhoI, ~ont~ning the putative control 
elements for expression in neural tissue. 
The construct XHTag was designed to test whether intra- 
genie or 3’ sequences are involved in regulation of CRABP- 
I expression. It starts at the XhoI site 1 kb upstream of the 
CRABP-I gene and ends at the Hind111 site 2 kb after the 
fourth exon. In comparison to GCTag it lacks 2 kb of 5’ 
sequences, but still contains all the exons and introns. Four 
out of five lines expressed the transgene. Strikingly, the 
pattern of expression of XHTag is complements to the 
one found with ECTag and includes the limb bud, migrating 
neural crest cells, dorsal root ganglia, otic vesicle, mesench- 
yme in the mesonephric area and cells in the dorsal aspect of 
the neural tube (Figs. 2E-G and 3C,D). The latter are cells 
that are believed to have retained the potency to form neural 
crest (LeDouarin, 1982; Bronner-Fraser and Fraser, 1988). 
The limb buds of XHTag mice also show a proximoldistal 
gradient of CRABP-Tag with the highest expression distally 
(Fig. 2G). 
The pattern seen with GCTag can be reconstructed by 
overlaying the expression patterns of ECTag and XHTag. 
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This shows that the CRABP-I gene is regulated via at least 
two independent enhancer regions, one region responsible 
central nervous system. The restricted expression pattern 
for the neural component of its expression, located upstream 
of CRABP-I suggests it may be involved in patterning the 
of the gene and one responsible for its mesenchymal/neural 
CNS. We wanted to know whether the CRABP upstream 
elements could also act as independent enhancers. There- 
crest component, located downstream from exon II. fore, we cloned the 2 kb EcoRUXhoI upstream fragment 
2.3. Deletional analysis of the neural enhancer fragment 
onto a heat shock promoter (hsp68)/LacZ gene, resulting 
in construct EXhspZ (ZO, Fig. 4). The hsp68/LacZ construct 
RA has profound effects on the morphogenesis of the 
does not give any constitutive expression in transgenic 
mouse embryos, making it a useful vector for testing the 
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Fig. 4. Deletional analysis of the 5’ region of CRABP-I. (A) Genomic map of the CRABP-I locus. (B) Map of construct EXp61OZa (ZO), which contains 2.14 
kh of CRABP-I upstream sequences driving the hsp68 minimal promoter, the LacZ gene and the SV40 polyadenylation signal. (C) Microinjection fragments 
derived from construct EXpblOZa. The table on the right shows the expression in transgenic mice. The first column indicates the name of the construct, he 
second column gives the total number of transgenic mice with that construct, he third column indicates me number of LacZ expressing mice and the fourth 
column shows the number of mice that expressed La& in the neural subdomain of the CRABP-I expression pattern. neural band, band of X-gal staining cells 
in the bottom third of the neural tube of tmnsgenic embryos. 
Fig, 2. Immunohistochemical analysis of GCTag, XHTag and ECTag transgenic mouse embryos at 10.5 d.p.c. Sections were incubated with an antibody 
against CRABP-I and stained with DA& (A,E,H), or with a monoclonal antibody against he Myc epitope tag and stained with BClP/NBT (B-D,F,G,I). 
Sections of transgenic embryos with construct GCTag. The full CRABP-I expression pattern is reproduced by the transgene, with expression found in the 
midbrain, hindbrain, neural tube, dorsal root ganglia, limb bud and frontonasal mesenchyme (A-D). Rhombomere specific staining is seen at a Iow level in 
rhombomere 2 and at a higher level in rhombomeres 4. 5 and 6 (C). Staining in the timb bud shows a gradient along the proximo/dis~l axis with highest 
levels of staining found at the distal ends (D,G). Sections of a transgenic embryo carrying cons~ct XHTag. Myc-tag staining is found in mesenchyma~ and 
neural crest tissue, but not in neura! tissue. The lack of transgene xpression i  the midb~n is evident (E-G). Transgene xpression in an XHTag embryo 
shows the expression i  the neural crest and the proximo/distal gradient in the limb bud (G). Sections of an embryo from an ECTag transgenic line (H,I). The 
transgene (I) is expressed only in neural cells that form a subset of the CRABP-I expressing cells (HI. FB, forebrain; MB, midbrain; HB. hindbrain; H. heart: 
FNM, frontonasal mesenchyme; LB, limb bud; DR, dorsal root ganglia; NC, neural crest. 
Fig, 3. Expression patterns of tagged CRABP-I in the neural tube of 10.5 d.p.c. embryos. Sections were incubate with a CRABP-I antibody and stained with 
DAB (A,C,E) or incubated with an Myc-tag antibody and stained with BCIPiNBT (B,D,F). GCTag transgenic embryos how expression in the man& layer 
of the neural tube. in the dorsal root ganglia nd in the neural crest cells migrating on either side of the neural tube (A,B). XHTag containing embryos express 
the transgene in the dorsal aspect of the neural tube and in the migrating neural crest cells (C,D), while ECTag transgenic embryos express the transgene in
the mantle layer of the neural tube except in the dorsal most portion (E,F). DR. dorsal root ganglion; NC, neural crest cells; NT, neural tube; ML, mantle 
layer. 
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Fig. 5. X-gal staining of LacZ transgenic embryos. (A,B) Transgenic embryos for construct 24 show LacZ expression in the midbrain, hindbrain, cranial 
nerves and neural tube. (C) Cross section of an X-gal stained Z4 embryo to indicate the staining pattern in the outer layer of the midbrain and hindbrain. (D) 
Section of a transgenic embryo showing X-gal staining in the mantle layer of the neural tube. (E) Cross section of the neural tube of a transgenic embryo with 
construct 22, showing a band of X-gal staining at the ventral side, peculiar to only constructs Zl and 22. 
presence of regulatory elements in heterologous sequences 
(Kothary et al., 1989). A series of deletion constructs was 
made from ZO (Zl -Zl 1) and the results of these transgenic 
experiments are compiled in Fig. 4.Z4 was expressed in the 
neural CRABP-I expressing cells in the midbrain, hindbrain 
and neural tube (Fig. 5), consistent with the pattern found 
for ECTag. Within the 24 fragment the sequences between 
BglII-NheI and XbaI-XhoI are found to be important for the 
expression of LacZ in neural tissue. Both of these smaller 
fragments are required since constructs ZS, ZlO and Zll 
show correct expression of the LacZ gene, whereas the con- 
structs Z5, 26, 27 and Z9 do not. For each of these con- 
structs one or more embryos were obtained showing LacZ 
expression in ectopic tissues due to a position effect. Inter- 
estingly Zl and 22 show consistent but aberrant expression 
of the LacZ reporter gene in a specific band in the neural 
tube (Fig. 5E). The significance of this for regulation of the 
endogenous CRABP-I gene is unclear, as this is not a site of 
CRABP-I expression. It may be an artefact created by pla- 
cing the fragment in an unnatural environment. 
2.4. Molecular dissection of the neural CRABP-I enhancer 
To further dissect the BglII/NheI and XbaI/XhoI frag- 
ments that make up the neural enhancer of CRABP-I, DNA- 
se1 footprinting analysis was performed with nuclear 
extracts, made from dissected midbrain, hindbrain and 
neural tube tissue from approximately 120 I 1.5-day-old 
mouse embryos (Fig. 6). Three distinct protected regions 
were seen in the XbaI-XhoI fragment (XXI, XX2 and 
RARE) and one region in the BglII/NheI fragment (BN2). 
The RARE area contains a direct repeat (DR) with half-site 
sequences closely matching the AGGTCA consensus 
sequence found in other nuclear hormone receptor esponse 
elements (Leid et al., 1992). The motif is AGGTCCT- 
TAAAGGTCA (in reverse orientation) and has a spacing 
of 4 bp between the half-sites (DR-4), which is normally 
associated with binding of a thyroid hormone (TR)/retinoid 
X receptor (RXR) heterodimer (Umesomo et al., 1991), but 
can also be a response lement for RAR/RXR heterodimers 
(Leid et al., 1993; Mader et al., 1993). Alternatively, itcould 
bind the orphan receptor NGFI-B, having a perfect match to 
the reported AAAGGTCA consensus binding site for this 
factor. 
To confirm that the protected areas that were identified in 
the footprinting assays indeed correspond to transcription 
factor binding sites we performed bandshift experiments 
with oligonucleotides covering these protected areas. All 
four elements (oligos BN2, XXI, XX2 and RARE) showed 
a number of retarded bands on the gel that were specific 
since competition with a lo-fold excess of non-radioactive 
oligo (self) abolished these retarded complexes (Figs. 7 and 
8). 
We first tested an oligo RARE, encompassing the puta- 
tive RA response lement, in bandshift assays. Competition 
experiments with radioactively labelled oligo RARE and 
excess of unlabelled mutated oligonucleotides were carried 
out. The mutation of one of the half-sites in such a way that 
the putative NGFI-B binding site is lost, but a new palin- 
dromic repeat is generated (oligo RAREMut) has very little 
effect on binding of the factor(s) to this oligo. Changing the 
spacing between the half-sites (oligo RARE7) from 4 to 7 
resulted in only a slight loss of ~om~tition ability, indicat- 
ing that the spacing plays a minor role in the binding proper- 
ties of this element. However, when both half-sites were 
mutated (oligo RAREA2) the ability to compete was lost 
completely. Competition with the DR-5 RARE from the 
RAR/3 gene was also effective, indicating that the factor 
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Fig. 6. DNAseI footprinting analysis of the CRABP-I neural enhancer region. (A) The BglIUNheI and XbaI/XhoI fragments required for CRABP-I expression 
in neural tissue were subjected to DNAseI footprinting analysis. The BglIUNheI fragment spans the region from -2280 to -2015 and the XbaI/XhoI fragment 
spans the region from -1360 to -1OM3 relative to the start of the coding region of the gene. The fragment used in each of the assays is indicated above the gel 
with the labelled end marked by an asterisk. The labelled fragments were incubated with 5, lo,20 or 40 fig of nuclear extract prepared from excised neural 
tubes, midbrains and hindbrains from 11.5 d.p.c. embryos before digestion with DNAseI. Only DNAseI (no extract) treated DNA is shown by -. A G + A 
Maxam and Gilbert sequence reaction is run along with each of the assays. The regions protected by the nuclear extract are indicated as BN2, XXI, XX2a. 
XX2b and RARE. The arrow indicates ahypersensitive site. (B) Map of the protected elements on the two fragments. Nucleotide sequences ofthe footprmt- 
containing parts of the BglWNheI and XbaUXhoI fragments. The regions that show a footprint in (A) are indicated by boxes. The two T residues in italics in 
clement BN2 indicate that these residues differ from the published sequence. The arrow between XX2a and XX2b indicates the position of the h~rsensitive 
site. The region RARE contains a DR4 RA response lement, of which the half-sites are rndicated in bold face. 
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Fig. 7. Bandshift assay on the putative CRABP-I retinoic acid response element (RARE). A iabelled double stranded oligonucleotide from the wild-type 
CRABP-I RARE element was incubated with 3 gg of embryonic neural nuclear extract in the presence or absence of various mutated oligonucleotides (a-c) 
or the RARE element from the RARfl2 promoter (d). Competitor a is oligo RARE7, competitor b is oligo RAREMut, competitor c is oligo RAREAZ and 
competitor d is oligo P-RARE. Addition of antibodies against RARo, RARyl and RXR (cr, 6, y) resulted in a supershift of the retarded complexes. The panel 
with the labelled RARP2 RARE oligonucleotide as probe @RARE) is included as a control as this oligo is known to bind RAR/RXR heterodimers and the 
antibodies have been shown to be effective on these complexes. The specific retarded complexes are indicated by C, white the supershifted complexes are 
indicated by S. 
binding to the CRABP-I response element could be a RAR/ 
RXR heterodimer. We tested this hypothesis by adding anti- 
bodies against RARo, RARyl and RXR (all RXRs) in the 
bandshift and found that the antibodies did indeed supershift 
the complex formed on the RARE element (Fig. 7). The 
weaker supershift observed with the RARar and RARyl 
Bandshift assays with the BNZ, XX1 and XX2 elements 
antibodies compared to the RXR antibody is likely to be 
showed the formation of three to five complexes on each of 
these elements (Fig. 8). Competition experiments were also 
performed on these elements. We designed three system- 
due to a lower titer of these antibodies or could possibly 
atically mutated oligonucleotides (oligos xX1.1, Xx1.2 and 
Xx1.3). The mutation in Xx1.3 did not interfere with its 
indicate that RAR/3 is involved in the complex binding to 
ability to compete with labelled oligo Xx1. Oligo Xx1.2 
the element. 
had completely lost the ability to compete, indicating that 
the binding sites are located in the mutated part of the oligo, 
i.e. in the CCTGTGT sequence, or at least comprise part of 
this sequence. The oligo XXI.1 appears to compete for 
some of the retarded bands, but has lost the capability to 
compete for one of those bands (indicated by arrow number 
4 in Fig. 8). Since this com~tition is also lost in the experi- 
ment with oligo Xx1.2 the recognition sequence for this 
p~icular factor is expected to overlap the sequences 
mutated in these oligos. The band indicated by arrow num- 
ber 5 could be AP-1 as the intensity of this band is much 
reduced when an AP-I oligo is added as a competitor. The 
The element XX2 shows a shift which is largely com- 
peted out by addition of an oligo containing two consensus 
identity of the factors binding to the XX1 element remains 
AP- 1 sites, suggesting that this element also binds an AP- l- 
like factor. The retarded compiexes found on the element 
at this stage unknown. The binding of these factors to XX1 
BN2 are reminiscent of the complexes found on a regulatory 
is, however, tissue specific as is shown by the fact that the 
element found in the Thy1 promoter (Spanopoulou et al., 
1991). However, no competition is found with oligos con- 
retarded complexes 1 and 4 are not found with extracts from 
taining Spl or AP-1 binding sites. 
MES-1 or MEL cells. 
Interestingly, during the footprinting analysis of the 
BglII/NheI fragment we discovered a difference between 
the published sequence of this CRABP-I upstream region 
and our own sequence, located exactly in the BN2 element. 
The importance of the differing residues is shown by the 
observation that an oligo, containing the published sequence 
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Fig. 8. Bandshift assays with oligonucleotides encompassing the sequences that were found to be protected in the DNAseI f~tp~nting assay. The radio- 
actively labelled oligonucleotide used as probe in each experiment is indicated above the gel. A IOO-fold excess of the following unlabeled competitors was 
used in the lanes indicated: a. oligo Xx1.1; b, oligo Xx1.2; c, oligo Xx1.3; d, oligo 2*Spl; e. oligo 2*AP-1; f, oligo BNI. The arrows on the left of the panel 
with oligo XXI indicate specific complexes. The band indicated by arrow 2 is considered aspecific as it also appears when unlabeled oligo XX1 (self) is 
added as a competitor. 
plus an additional mutation, did not give a bandshift and was 
unable to compete with BN2 (Fig. 8). 
3. Discussion 
The CRABP-I gene shows a specific expression pattern 
during embryonic development. As retinoic acid is critically 
involved in pattern formation of vertebrate mbryos, the 
spatiotemporally restricted expression of CRABP-I suggests 
it may be involved in controlling the level of RA in different 
tissues of the embryo. An underst~ding of the factors that 
control expression of CRABP may provide further insight 
into the mechanisms of RA signal transduction during 
emb~ogenesis. Fu~he~or~, identification of the cis-acting 
elements would allow manipulation of CRABP-I levels or 
related proteins in specific tissues in the embryo. We have 
therefore investigated the molecular mech~isms that are 
involved in the regulation of CRABP expression in trans- 
genie mice. We show here that multiple sets of enhancer 
elements are employed by the gene. The complete spatial 
and temporal expression pattern of the gene was reproduced 
in transgenic mice with the 40 kb cosmid M4Tag, which 
contains the complete CRABP-I coding region plus an 
inserted epitope tag. The same expression pattern was also 
found in mice transgenic for the 16 kb construct GCTag, 
containing the complete coding region of the gene, includ- 
ing intragenic sequences as well as 3 kb of upstream and 2 
kb of downstream sequences. The CRABP-Tag transgene is
expressed from these constructs in the outer layer of the 
midbrain, the hindbrain and the mantle layer of the neural 
tube, in neural crest, limb buds, in the mesonephric 
mesenchyme and in the frontonasal mass, i.e. all known 
CRABP-I expression sites in the embryo. 
In the limb bud we observed aproximo/distal gradient of 
the transgene with the highest expression levels found dis- 
tally, consistent with the expression observed by others 
(Dolle et al., 1989). However, the existence of an anterior/ 
posterior gradient is less clear. A gradient with the highest 
level anteriorly has been reported by some (Maden et al., 
1988; Perez-Castro et al., 1989), while the absence of a 
gradient has been reported by others (Dolle et al., 1989; 
Ruberte et al., 1992). Our results support he observations 
of Dolle and Ruberte since we did not find consistent evi- 
dence for an antero/poste~or gradient in the limb bud. 
In some of the transgenic lines with M4Tag and GCTag 
expression of the transgene could not be detected in the 
frontonasal mass. These lines were shown by $1 analysis 
to have an overah low level of expression of the transgene 
compared to the endogenous gene (data not shown) and thus 
the expression in the frontonasal mass probably rem~ned 
below the detection level in those lines. In the lines that 
exhibit a high level of CRABP-Tag expression relative to 
the endogenous CRABP-I a clear expression of the trans- 
gene was found in the frontonasal mass. In all lines with 
M4Tag and GCTag the level of expression was lower than 
would be expected from the copy number of the transgene. 
This suggests the presence of an additional regulatory ete- 
ment that is involved in controlling the level of expression. 
Clearly the proximal promoter egion of CRABP-I alone, 
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as represented by the constructs XCTag or SCTag, is insuf- 
ficient to drive expression of the gene. In summary, we 
conclude that all the c&acting elements required for the 
regulation of the correct spatio-temporal expression of 
CRABP-I are located within a 16 kb fragment GCTag. 
3.1. Distinct enhancers drive the expression of CRABP-I in 
neural and in mesenchymaUneura1 crest tissue 
Further dissection of the construct GCTag revealed that 
the tissues that express CRABP-I during mouse embryonic 
development can be divided into two groups. Different sets 
of enhancers are used to drive the expression of CRABP-I in 
these tissues. Constructs containing the upstream region of 
GCTag, but lacking most downstream sequences, i.e. 
ECTag, show expression of the transgene in a neural sub- 
domain of the CRABP-I expression sites. Constructs with 
the downstream region from GCTag, but lacking an 
upstream fragment, i.e. XHTag, drive expression of 
CRABP-Tag in a subdomain of CRABP-I which contains 
mesenchymal nd neural crest cells. Expression of CRABP- 
I in the latter group, which contains neural crest cells, 
including those of the dorsal root ganglia and in the otic 
vesicle and the mesenchyme in the mesoneph~c area and 
the limb bud, is apparently regulated via enhancer(s) located 
downstream of the second exon of the gene, as these cells 
express CRABP-Tag from the construct XHTag, but not 
from ECTag. Their identification in the future may provide 
a useful tool in the study of the development of the limb bud 
and neural crest. 
The second group of cells that express CRABP-I during 
murine development is formed by the celis in the outer layer 
of the midbrain, the hindbrain and the ventral part of the 
mantle layer of the neural tube. These cells show expression 
of the transgene in mice containing the construct ECTag. 
This neural CRABP-I enhancer must hus be localised in the 
2 kb EcoRI/XhoI upstream fragment from -3200 to -1100 
relative to the gene. We show that this region can act as an 
independent enhancer on heterologous promoters ince it is 
also able to drive LacZ expression in the same neural tissue 
when cloned into an hsp68LacZ vector (24, Fig. 4). A more 
precise definition of the cis-acting elements through injec- 
tion of a series of deletion mutants (Z5-Zi 1, Fig. 4) showed 
a requirement for the presence of two fragments of 270 and 
350 bp. 
The constructs Zl and 22 which contain sequences 
further upstream of the CRABP-I promoter region also 
drove expression of the LacZ reporter gene in transgenic 
embryos. However, the LacZ expression with these con- 
structs was consistently found in a particular band in the 
bottom third of the neural tube, throughout its thickness 
(Fig. 5E). No endogenous CRABP-I expression is detected 
at that particular site in the neural tube. Although it is remi- 
niscent of CRABP-I expression found at later developmen- 
tal stages in the commissural neurons of the neural tube 
(Maden et al., 1992; Ruberte et al., 1992), we presently 
believe it to be an artefact caused by taking the element 
out of its normal environment, resulting in the ectopic acti- 
vation of the element. 
3.2. Specific cis-acting elements are required for CRABP-I 
neural enhancer activity in the developing nervous system 
DNAseI footprinting analysis of the two upstream frag- 
ments revealed four protected regions that we termed BN2, 
XXI, XX2 and RARE. B~dshift assays with oligonucleo- 
tides encompassing the protected sequences how that 
indeed protein/DNA complexes are formed on these ele- 
ments. The element RARE contains a nearly perfect con- 
sensus recognition site for nuclear hormone receptors (Leid 
et al., 1992) consisting of a direct repeat (DR) with a spa- 
cing of four nucleotides (DR-4). A DR-4 element is usually 
indicative for binding of thyroid hormone receptor/retinoid 
X receptor heterodimers (TR/RXR) (Umesomo et al., 1991), 
but depending on the context of the repeat, binding of RAW 
RXR heterodimers to certain DR4 elements has also been 
found (Nagpal et al., 1992; Mader et al., 1993). A DR-4 
element is part of a complex response lement in the laminin 
Bl gene, which is induced by RA in F9 teratocarcinoma 
cells (Vasios et al., 1989). We have used antibodies against 
RARor, RARyl and RXR (all isoforms) to show that the 
complex binding to the CRABP-I RARE contains both 
RARs and RXRs and thus is most likely an RAR/RXR 
heterodimer. This is the first identification of an RA 
response lement in the promoter of the CRABP-I gene. 
However, it is not surprising considering that the genes of 
almost all other proteins involved in the RA signal transduc- 
tion pathway contain RAREs in their promoters. Upregula- 
tion and ante~o~sation f CRABP-I expression has been 
found in the developing nervous ystem of mouse embryos 
after RA treatment, when the RA was administered within a 
particular developmental time period (7-8.5 d.p.c.) (Leo- 
nard et al., 1995). An upregulation of CRABP-I expression 
by RA in P19 cells has also been reported. but was consid- 
ered to be an indirect effect as protein synthesis was found 
to be required (Wei et al., 1989). Recently it has been shown 
that CRABP-I is upregulated in ABl cells after treatment 
with RA at low concentrations, which are in the concentra- 
tion range that is found in the embryo, but that this effect is 
abolished at higher RA concentrations (Chen and Gudas, 
1996). This may explain why in some studies no upregula- 
tion of CRABP-I was detected after treatment of embryos 
with an excess of RA (Harnish et al., 1992). 
One of the factors binding to the elements XX1 and XX2 
could be AP- 1 or an AP- 1 -like factor, as an oligo containing 
two AP- 1 consensus sites largely competed with some of the 
complexes formed on these elements. Both elements con- 
tain sequences that resemble an AP-1 recognition site. The 
other factors binding to Xx1, XX2 and BN2 remain uni- 
dentified. The elements do not contain recognisable consen- 
sus sequences for binding sites of known transcription 
factors. Thus, the sequence of these binding sites may 
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have diverged from the consensus or the elements may con- 
tain binding sites for novel transcription factors. Two uni- 
dentified complexes on the XX1 element are tissue specific, 
since neither of them is formed with nuclear extract from 
CRABP-I expressing MES-1 cells or non-expressing MEL 
cells (Fig. 8). 
The elements that have been identified in this study are 
located on different ~agments from the ones that were 
recently reported to be important for expression of 
CRABP-I in 3T6 and Pi9 cell lines (Wei and Chang, 
1996). In our own studies we have also found that the 
expression of CRABP-I in the highly expressing cell lines 
MESl and Tera2 is regulated ifferently to that in mouse 
embryos, since the fragments that direct CRABP-I expres- 
sion in the mouse embryo are unable to drive expression of 
the chloramphenicol acetyltransferase (CAT) gene in those 
cells in transient transfection assays. This discrepancy 
shows that, at least in the study of the CRABP-I promoter 
region, cell lines are inadequate as a model for complex 
tissues in vivo. Bandshift experiments with oligonucleotide 
XX1 have shown that specific retarded complexes that are 
formed with the nuclear extract from excised neural tissue 
are absent when MES- 1 or MEL cell nuclear extract is used, 
indicating that the element XX1 binds different regulatory 
factors in different issues or cell lines. In addition it is likely 
that the local chromatin environment plays an important 
role in the spatiotempor~ specific regulation of the 
CRABP-I gene and this factor is clearly not taken into 
account in transient transfection assays. 
In summ~, we show that the expression pattern of 
CRABP-I during murine embryonic development consists 
of two separate xpression domains and that distinct enhan- 
cer elements are involved in the transcriptional regulation of 
the gene in these expression domains. The expression of 
CRABP-I in the neural subdomain i volves a complex inter- 
play of regulatory factors at multiple enhancer elements. 
One of these elements is a putative RA response lement 
with a 4 bp spacing (DR-4) which is shown to bind RARs 
and RXRs, presumably as heterodimers, allowing for mod- 
ulation of CRABP-I expression by its own ligand. 
4. Experimental procedures 
4.1. Constructs 
A 5500 bp genomic EcoRI fragment ~on~ning exons I 
and II of the mmine CRABP-I gene was subcloned and the 
C at position +4 of the coding sequence was changed to a G 
by site-directed mutagenesis, thus creating an NcoI site at 
the translational start site. A 30 bp sequence coding for a 10 
amino acid c-myc derived tag (Evan et al., 1985) was cloned 
into this site to create pDJTag. Addition of the 3’ end of the 
gene to pDJTag resulted in pGCTag (see Fig. 1). The micro- 
injection fragments GCTag and XHTag were isolated from 
this plasmid. The cosmid M4Tag was created by adding 5’ 
and 3’ flanking regions back to GCTag. pECTag was con- 
structed by linking the cDNA sequences for exons II, III and 
IV in frame to exon II of pDJTag. The microinjection frag- 
ments ECTag, SCTag and XCTag were all derived from this 
plasmid. 
The LacZ reporter constructs were made by cloning the 
fragments EcoRl-Eco47111, Eco47111-MscI and EcoRl- 
XhoI onto the hsp68 minimal promoter, the LacZ gene 
and the SV40 polyadenylation signal (Kothary et al., 
1989). This resulted in the constructs EE47hspZ, 
E47MhspZ (Z5) and EXhspZ (ZO), respectively. Microin- 
jection constructs 21 and 22 were made from EE47hspZ. 
Construct AABhspZ (23) was made by deleting an AvrIL’ 
BglII fragment from EE47hspZ. Z4,Z6 and 27 were made 
from EXhspZ (ZO). Construct AMXhspZ (ZS) was made by 
deleting an MsclKbaI fragment from EXhspZ. Both 28 and 
Z9 were derived from this construct. Deletion of an NheV 
XbaI fragment from EXhspZ (ZO) created ANXhspZ (ZlO). 
The fragments 210 and Zl 1 were made from this construct. 
4.2. Transgenic mice production and prucessing of the 
embryos 
Microinjection was performed according to standard pro- 
cedures (Hogan et al., 1994). Transgenic mice and embryos 
were identified by Southern blot analysis. Embryos were 
collected at midgestation~ stages. For detection of Myc- 
tagged CRABP-I the embryos were washed in PBS (phos- 
phate buffered saline) and fixed for 1 h in 35% methanol, 
35% acetone and 5% acetic acid. For staining with X-gal, 
embryos were fixed in 1% formaldehyde, 0.2% glutaralde- 
hyde, 2 mM MgC12, 5 mM ethylene glycol-bis(beta-ami- 
noethyl ether) ~,~,~,~-tetraacetic acid (EGTA) and 
0.02% Nonidet P-40 (NP-40). 
4.3. Analysis of the embryos 
After fixation, transgenic embryos containing the Myc- 
tag were dehydrated, embedded in paraffin and sectioned. 
After rehydration through ethano~xylene, aspecific binding 
was blocked by pre-incubating the sections in PBS/Tween- 
20 containing 2% NGS (normal goat serum). To eliminate 
endogenous peroxidase activity the sections were preincu- 
bated with 0.3% H202 in PBS. The sections were incubated 
overnight at 4°C with primary antibodies against CRABP-I 
or the Myc epitope in a 1: 100 dilution in PBS containing 1% 
BSA and 0.05% Tween-20. The sections that were incu- 
bated with the CRABP-I antibody were then incubated 
with a 1: 100 dilution of peroxidase conjugated swine anti- 
rabbit antibody for 3 h. Next the sections were exposed 
to 0.04% diaminobenzidine t trahydrochloride (DAB) in 
0.05 M Tris-maleate buffer (pH 7.6) with 0.006% H202. 
The Myc~pitope ~tib~y incubated sections were 
incubated with an alkaline phosphatase conjugated goat 
anti-mouse antibody and then exposed to nitro blue 
te~~~olium chloride/S-bromo-4-chloro-3-indolyl phosphate 
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(NBT/BCIP). Finally, the stained sections were dehydrated 
and mounted. 
Embryos transgenic for LacZ constructs were stained for 
several hours or overnight at 37°C in the dark in a solution 
containing 5 mM K3Fe(CN),, 5 mM IQFe(CN)6.3H20, 2 
mM MgC12, 0.01% sodiumdeoxycholate, 0.02% NP40 and 
0.1% 5-bromo-4-chloro-3-indolyl-P_D-galacto-pyranoside 
(X-gal). 
4.4. DNAsei footprinting analysis 
The midbrain, hindbrain and neural tube were excised 
from approximately 120 embryos at 11.5 d.p.c. Crude 
nuclear extracts were prepared from the excised tissue as 
described (Andrews and Failer, 1991). The fragments BglII/ 
NheI, XbaIiXhoI and SacIlHincII corresponding to the 
-2280 to -2015, -1360 to -999 and -1171 to -986 
upstream CRABP-I regions, respectively, were footprinted 
as described (de Boer et al., 1988). Gels were dried and 
exposed using a PhosphorImager (Molecule Dynamics). 
4.5. Electrophoresis mobility shift assay 
Oligonucleotides (Eurogentec) corresponding to the 
DNAseI footprints were analysed by EMSA as described 
(de Boer et al., 1988). The following oligonucleotides 
were used as probes or competitors (coding strand 
sequences are listed; in competitor oligos mutated nucleo- 
tides are indicated by lower case letters): oligo XXI, 
GAATTTTACAACACCTGTGTCATGAGGAGTG; oligo 
xx1.1, GAATTggcaccaACCTGTGTCATGAGGAGT; 
oligo xx1.2, GAATTTTACAACAaagtttgCATGAG- 
GAGT; oligo XX 1.3, GAA~ACAACACCTGTG- 
TacgtcttAGT; oligo RARE, A~AAAAGTGACCTT- 
TGGGGACCTCGAGCA; oligo RARE7, AGGAAAAGT- 
GACCTTTGGttcGGACCTCGAGCA; oligo RAREMut, 
AGGAAAAGgt~aag~GGGGACCTCGAGCA; oligo 
RAREA2, AGGAAAAGctgaag~GGta~agaCGA~ A: 
oligo XX2, AGAAGGAATCCTGTCAA~CCGAGGAA- 
AGTAATCTGCTTAGGACCT; oligo BNl, AACCAT- 
GAATCCCTCCCACAACCC; oligo BN2, AACCAT- 
GAATCCCTCCGACTTCCC; oligo P-RARE, CCGGGT- 
AGGGTTCACCGAAAGTTCACTCG; oligo 2*AP-1, 
GAAACCTGCTGACTCAGATGTCCTGAAACCTGCT- 
GACTCAGATGTCC~ oligo Z*Sp 1, AAATAGTCCCG- 
CCCCTAACTCCGCCCAT. For each competition experi- 
ment a lOO-fold excess of non-radioactive double stranded 
oligonucleotide was added. For the supershifts with oligo 
RARE, antibodies against RAR~Y {Ab9ar), RARyl (Ably11 
and RXR ((u, 8, y) were kindly provided by C. Rochette- 
Egly and P. Chambon (R~hette-ugly et al., 1991). After 
incubating the oligo with nuclear extract for 15 min, 1 ,ul of 
ascite fluid antibody was added to the mixture and incubated 
for another 15 min. After electrophoresis the gels were 
dried and exposed using a Phosphorlmager (Molecular 
Dynamics). 
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